Skip to main content

Table 2 Overview of completed randomized controlled trials performed in paediatric rheumatology patients treated with bDMARDs/JAK inhibitors (July 2020)

From: Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – what we know and what we do not know from randomized controlled trials

Drug Class Drug Studies Arms Patients Indications Populations
Anti-CD 20 agent rituximab 0     
CD80/86 inhibitor abatacept 1 2 190 JIA PJIA, SJIA (without systemic features), extended OJIA
IL-1 inhibitor anakinra 2 4 110 JIA PJIA, SJIA
canakinumab 2 4 261 JIA SJIA
rilonacept 2 5 95 JIA SJIA
IL-6 inhibitor sarilumab 0     
tocilizumab 3 6 356 JIA PJIA, extended OJIA, SJIA
IL-12/23 inhibitor ustekinumab 1 3 110 Psoriasis Plaque psoriasis
IL-23 inhibitor guselkumab 0     
risankizumab 0     
tildrakizumab 0     
IL-17 inhibitor brodalumab 0     
ixekizumab 1 3 201 Psoriasis Plaque psoriasis
secukinumab 0     
TNF inhibitor adalimumab 6 13 485 JIA, psoriasis, uveitis ERA, JIA-associated uveitis, PJIA, plaque psoriasis
etanercept 8 17 746 JIA, psoriasis, vasculitis PJIA, OJIA, PsA, ERA, SJIA, plaque psoriasis, KD
golimumab 1 2 154 JIA PJIA, SJIA (without systemic features), PsA
infliximab 6 13 576 JIA, uveitis, vasculitis PJIA, non-infectious uveitis, KD
certolizumab pegol 0     
BAFF inhibitor belimumab 1 2 93 CTD SLE
JAK inhibitor tofacitinib 1 2 225 JIA ERA, PJIA, PsA
baricitinib 0     
upadacitinib 0     
  1. Abbreviations: IL interleukin, TNF tumour necrosis factor, JAK Janus Kinase, JIA juvenile idiopathic arthritis, CTD connective tissue disease, PJIA polyarticular juvenile idiopathic arthritis, KD Kawasaki disease, SJIA systemic juvenile idiopathic arthritis, OJIA oligoarticular juvenile idiopathic arthritis, ERA enthesitis-related juvenile idiopathic arthritis, PsA psoriatic juvenile idiopathic arthritis, SLE systemic lupus erythematosus
\